AstraZeneca’s EMERALD‑3 Phase III study demonstrated a statistically significant and clinically meaningful improvement in progression‑free survival for patients with embolization‑eligible, unresectable hepatocellular carcinoma. The combination of Imfinzi (durvalumab) and Imjudo (tremelimumab) with lenvatinib and transarterial chemoembolization (TACE) outperformed standard care, which consists of TACE alone, and a trend toward improved overall survival was observed in the interim analysis.
Continue reading for full analysis...
AstraZeneca reported that its interleukin‑33 biologic, tozorakimab, achieved the primary endpoint in both the OBERON and TITANIA Phase III trials for chronic obstructive pulmonary disease (COPD). The studies showed a statistically significant and clinically meaningful reduction in moderate‑to‑severe exacerbations among patients, including former smokers and a broad patient population.
Continue reading for full analysis...
AstraZeneca announced the construction of a cell‑therapy manufacturing and innovation centre in Shanghai, establishing the first global drugmaker with end‑to‑end cell‑therapy capabilities in China.
Continue reading for full analysis...
Health Canada approved AstraZeneca’s rare‑disease drug Koselugo (selumetinib) on March 9, 2026 for adult patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas.
Continue reading for full analysis...